Related by context. All words. (Click for frequent words.) 73 Phase III PREGNANT PROCHIEVE 73 PREGNANT PROCHIEVE ® 63 TCA Cellular 63 innovative Activated Checkpoint 62 Phase III Pivotal 62 candidate SMaRT Replacement 61 LUMINATE 61 Cardiac Stem Cell 61 Phase III multicenter 61 Vertebral Compression Fracture 60 Phase 2b MATRIX 60 Dr. Gabriel Lasala 60 Icy Hot Pro 60 Successfully Completes Phase 60 Refractory Angina 60 bile duct tumor 60 EnteroMedics proprietary neuroblocking technology 60 APEX PD 59 Phase Ib II 59 Andara TM OFS 59 BLOOM Behavioral modification 59 tramiprosate Alzhemed TM 59 CHAMPION PCI 59 First Patient Enrolled 59 Phase IIIb clinical 59 PF # [002] 59 Bipolar Depression 59 Initiates Enrollment 58 Aryplase 58 3 registrational trial 58 phase IIa clinical 58 VBLOC vagal blocking 58 randomized controlled multicenter 58 Biomarker Study 58 Bayer HealthCare Onyx Pharmaceuticals 58 SPEAR Study 58 DermaQuest ™ Skin 58 Hedgehog Pathway Inhibitor 58 Drug Shows Promise 58 candidate CRLX# 58 Phase Ib IIa 58 acyclovir Lauriad R 58 randomized Phase IIb 58 Extracorporeal Shock Wave 58 E1 INT TM 58 personalized cellular immunotherapy 58 Degarelix 58 Rilonacept 57 initiate multicenter 57 phase IIb trial 57 NABTT 57 Motesanib 57 oncolytic virus therapies 57 evaluating mipomersen 57 Phase III Clinical Trials 57 ALN VSP Phase 57 Phase IIIb study 57 ENDEAVOR IV 57 COSIRA trial 57 Phase IIIb 57 Advaxis Phase 57 BioSante LibiGel Phase III 57 ALISTA TM 57 Qnexa TM 57 Completes Patient Enrollment 57 onset AF 57 Oral Calcitonin 57 Phase III Psoriasis 57 NanoKnife IRE System 57 InterStim ® 57 Demonstrates Sustained 57 OPT CHF 57 Ellex 2RT 57 BRIM2 57 generation URAT1 inhibitor 57 Demonstrates Positive 57 Investigator Initiated 57 Fx #A 57 blinded randomized placebo controlled 57 Proton Beam 56 European Sepsis Trial 56 multicenter Phase II 56 Zemplar Capsules 56 pivotal bioequivalence 56 Syndax Pharmaceuticals Inc. 56 Phase III Clinical Trial 56 HCD# [002] 56 phase IIb clinical 56 OvaRex R 56 dose escalation phase 56 Valve Replacement 56 imetelstat GRN#L 56 Acute Decompensated Heart Failure 56 IMPACT DCM trial 56 midstage trials 56 telomerase therapeutic 56 Phase IIb clinical trials 56 IMPACT DCM clinical 56 Recurrent Glioblastoma 56 multicenter Phase 56 recurrent metastatic ovarian cancer 56 Initiates Clinical 56 Relapse Prevention 56 systemic Phase 1b 56 Ceflatonin R 56 Phase 2b Clinical Trial 56 Phase 2b kidney transplant 56 budesonide foam 56 INTEGRILIN R eptifibatide Injection 56 budesonide MMX Phase III 56 trial evaluating Prochymal 56 DIRECT Trial 56 Cardioxyl Pharmaceuticals 56 Xcellerated T Cells 56 Crofelemer budesonide foam 56 Phase 2b clinical trials 56 Initiates Phase II 56 AFREZZA TM 56 Testosterone MDTS ® 56 Cellular Therapies 56 zileuton IV 56 Psoriasis Drug 56 Phase 1b trial 56 Medtronic DBS 56 MKC# MKC# PP 56 CLARITY study 56 ALSYMPCA 56 Phase Ib clinical 56 evaluating Actimmune 56 phase IIa 56 EECP R 56 Guidelines Issued 56 REVIVE Diabetes 56 recombinant PSMA vaccine 55 Pivotal Phase III 55 CNS Disorders 55 mg/m2 cohort 55 Syncria albiglutide 55 Valvular Heart Disease 55 Initiates Phase III 55 Enrolling Patients 55 Pivotal Clinical Trial 55 MKC# MT 55 Fibromyalgia Syndrome 55 Helps Smokers Quit 55 Pertuzumab 55 phase IIIb 55 GetGoal Phase III 55 rALLy clinical trial 55 pharmacogenomic translational research 55 Pivotal Study 55 Study Shows Promise 55 randomized controlled Phase 55 BRIM3 55 Efficacy Trial 55 CUSTOM III 55 phase III ACCLAIM 55 Patient Enrollment 55 HDL Selective Delipidation 55 SUCCEED trial 55 VBLOC TM vagal blocking 55 Body Slimming 55 Prolonged Exposure 55 CEL SCI Phase III 55 Alzhemed TM 55 ActiPatch ® 55 Matrix Phase 2b 55 dimebon latrepirdine 55 Phase #/#a 55 Empatic ™ 55 Receives CE Marking 55 novel therapeutic antibodies 55 Pulmonary Arterial Hypertension 55 via intradermal injections 55 phase Ib 55 trastuzumab DM1 T DM1 55 midstage clinical 55 acute mania 55 ThermoDox ® clinical 55 Treatment Shows Promise 55 Completes Enrollment 55 CINQUIL 55 Colorectal Cancer Biology 55 phase Ib clinical 55 Androxal TM 55 SYMMETRY SM trial 55 Vicriviroc 55 PSMA ADC 55 evaluating Prochymal 55 BHT DNA 55 Submits Biologics License Application 55 Dupuytren Disease 55 vaccine Stimuvax 55 signal detection CTSD 55 Phase III placebo controlled 55 relapsing remitting MS RRMS 55 LibiGel Phase III 55 lorcaserin Phase 55 INSPIRE Trial Phase III 55 Phase 1b clinical trials 55 phase IIb study 55 initiated Phase Ib 55 CRLX# 55 Pain Therapy 55 Zenvia ™ 55 RhuDex 55 clinical trials SGN 54 Testosterone MDTS R 54 INS# [002] 54 VICTOR E1 54 ABSORB trial 54 Evaluation Program CTEP 54 Drug Fails 54 candidates Dyloject TM 54 Prostate Cancer Vaccine 54 Investigational Treatment 54 PROTECT AF 54 Initiates Clinical Trial 54 Daclizumab 54 TNFerade ™ 54 R#/MEM # 54 Demonstrate Significant 54 including eniluracil ADH 54 IIb clinical trial 54 UVIDEM 54 PRESEPT 54 STRIDE PD 54 Lupus Drug 54 Phase IIb Clinical Trial 54 Phase 1a clinical 54 Truvada tablets 54 Sleep Disturbances 54 serine protease inhibitor CU# 54 TEMSO 54 FOLOTYN ® 54 de novo kidney transplant 54 Renal Cell Cancer 54 novel orally inhaled 54 EDEMA3 54 multicenter multinational 54 features Loggerhead sea 54 EVIZON TM 54 Combination REOLYSIN R 54 Adjuvant Treatment 54 Acute Heart Failure 54 VIVITROL ® 54 Phase lll 54 phase IIb 54 Begins Dosing 54 Shows Promise Against 54 Randomized Phase II 54 HepeX B TM 54 PDE# inhibitors 54 Albugon 54 Restanza TM 54 Xcytrin R 54 OMP #R# 54 Phase IIa trials 54 Aggressive Reduction 54 CRMD# 54 IND Filing 54 Cerebril TM 54 Schizophrenia Treatment 54 Initiate Phase III 54 opioid induced bowel dysfunction 54 Albuferon Phase 54 orally inhaled migraine 54 Lung Cancer Drug 54 recurrent glioma 54 Phase #b/#a 54 ORAL Solo 54 Phase #b/#a clinical 54 Am J Manag 54 investigational monoclonal antibody 54 malignant mesothelioma Alfacell 54 Granted Orphan Drug 54 Vagus Nerve Stimulation VNS 54 BENLYSTA TM 54 RESTORE CLI trial 54 RE MODEL 54 Tyrosine Kinase Inhibitor 54 Pirfenidone 54 Glaucoma Treatment 54 Anturol TM 54 LibiGel ® testosterone gel 54 Phase 2a clinical 54 Preclinical Models 54 SPRYCEL ® 54 atypical Hemolytic Uremic Syndrome 54 Non Invasive Treatment 54 LibiGel testosterone gel 54 Aranesp Therapy 54 ENABLE Phase 2 54 solid tumors ZYBRESTAT 54 Therapeutic Antibodies 54 Prospective Randomized 54 Feasibility Trial 54 Telik Announces 54 hGH CTP Phase 54 Capesaris 54 Cardiac Resynchronization 54 PEGylated docetaxel 54 Prodarsan 54 lintuzumab SGN 54 confirmatory Phase 54 Phase III HEAT 54 Proellex TM 54 Genes Discovered 54 RNAi Therapeutics 53 Pivotal Trial 53 Advanced Melanoma 53 Inhaled Nitric Oxide 53 IIa trial 53 Renal Cancer 53 Mipomersen 53 initiate Phase IIb 53 Tyrosine Kinase Inhibitors 53 Prodarsan R 53 Slows Progression 53 CAPACITY trials 53 Allay TM Menstrual Pain 53 ENESTnd 53 GVAX ® 53 Treatment Reduces 53 ® natalizumab 53 Paroxysmal Atrial Fibrillation 53 TREAT ALS 53 Veterinary Oncology 53 AVN# Phase 53 confirmatory pivotal 53 Spero Pain Relief 53 apricitabine ATC 53 Frozen Shoulder Syndrome 53 candidate REP# 53 TNFerade TM 53 POSIDUR TM 53 Pivotal Phase 53 Gentamicin Surgical Implant 53 computerized cognitive behavioral 53 Prolongs Survival 53 nalbuphine ER 53 pralatrexate injection folate analogue 53 Transcatheter 53 Picoplatin Efficacy After 53 MKC# 53 ADVANCE PD 53 PRECISE Trial 53 Luveniq 53 Teva Provides Update 53 Cerebral Amyloid Angiopathy 53 ExCell study 53 Hematological Malignancies 53 IIa clinical 53 OvaRex ® MAb 53 data management Clintrial 53 Angiox ® 53 Diabetic Macular Edema DME 53 IMC #B 53 Malignant Glioma 53 Phase IIA 53 Phase III Trial 53 Hematology Molecular Pathology 53 randomized Phase 2b 53 cancer neuroendocrine tumor 53 Cethrin R 53 MEND CABG 53 Phase III 53 DEB# 53 FDA Approvals 53 Meets Primary Endpoint 53 evaluating intravenous picoplatin 53 cardiac myosin activator omecamtiv 53 Second Pivotal Phase 53 Dacogen injection 53 VALOR trial 53 MAGE A3 ASCI 53 TASKi3 53 PREOS R 53 clinical trials Archexin 53 generation rotary VAD 53 Additionally BioMimetic Therapeutics 53 SPIRIT FIRST 53 Clostridium difficile Infection 53 Somatuline R Autogel R 53 Initiates Phase 2b 53 forodesine 53 oral opioid modulator 53 reversing heparin 53 Plaque Psoriasis 53 Surgical Technique 53 telomerase inhibitor drug 53 antibody MAb 53 Files IND 53 AIMM trial 53 multicenter randomized Phase 53 Telik logo TELINTRA 53 KRN# 53 MIST II 53 PFO migraine 53 GATTEX ® 53 Phase 2a trial 53 Obtains CE Mark 53 Cites Positive 53 Submits Investigational 53 clinical trials dacetuzumab SGN 53 paclitaxel Taxol R 53 Initiate Phase 53 Phase III registrational 53 ADVANCE ILLUMINATE 53 Tesetaxel 53 fund BioSante LibiGel 53 intravenous RSD# 53 Gentle Path compound 53 IND submission 53 TELINTRA R 53 SPL# Gel vaginal microbicide 53 multicenter randomized clinical 53 Presents Positive 53 Cardiovascular Metabolic 53 Drug Prevents 53 Phase IIb Trial 53 mecarbil 53 PANVAC VF 53 albiglutide 53 CHDI Foundation 53 EGS# 53 metastatic hormone refractory 53 Hormone Receptor Positive 53 Fibrillex TM 53 Phase IIB 53 Diamyd Medical Diamyd 53 confirmatory Phase III 53 Phase III psoriasis 53 Personalized Oncology 53 Vitrasert R 53 Contrast Echocardiography 53 BR.# 53 FirstCyte 53 Phase III ADT 53 ongoing Phase IIIb 53 Chemotherapy Improves 53 multicenter Phase III 53 rALLy 53 Phase III confirmatory 53 registrational trial 53 Am J Geriatr 52 B Cell Malignancies 52 LUNESTA TM 52 EMPOWER ™ 52 ABSORB clinical 52 Gout Drug 52 number NCT# ClinicalTrials.gov 52 ELADUR ™ 52 Commences Phase 52 evaluating tesamorelin 52 OMAPRO ™ 52 Ostabolin C TM 52 individualized cellular immunotherapy 52 MEND CABG II 52 Acute Ischemic Stroke 52 Aflibercept 52 confirmatory Phase 3 52 Advanced Heart Failure 52 Phase 2b Trial 52 Immunotherapeutic 52 Therapeutic Antibody 52 Fibromyalgia Pain 52 phase III isavuconazole 52 Autism Speaks Autism 52 Improves Outcomes 52 Oral Anticoagulant 52 Phase III TRIST 52 Randomized Clinical Trials 52 Phase IIb trials 52 Targretin capsules 52 Zenvia Phase III 52 RANK Ligand inhibitor 52 allosteric modulator PAM 52 #:#-#,# CrossRef Medline [002] 52 Medidur TM FA 52 Therapy Improves 52 Intervention Effectiveness 52 NASH Huntington 52 bavituximab monotherapy trial 52 Recurrent Breast Cancer 52 VICTOR E3 52 Etanercept 52 Phase IIa clinical 52 FDA Approves Drug 52 Prostate AdenoCarcinoma Treatment 52 cetrorelix pamoate 52 Empatic TM 52 Acetavance TM intravenous acetaminophen 52 Biologics Manufacturing 52 Hormone Refractory Prostate Cancer 52 Phase Ib Clinical Trial 52 Randomized Study 52 ENGAGE AF TIMI 52 Phase IIb kidney transplant 52 PI3K/Akt pathway inhibitor 52 Proves Effective 52 Decompensated Heart Failure 52 ZACTIMA 52 Ocrelizumab 52 Systemic Sclerosis 52 Phase 2a Trial 52 IMA# 52 ToGA 52 Study Evaluating 52 HCV Protease Inhibitor 52 drug NP2 Enkephalin 52 CryoPlasty 52 Molecular Diagnostic Test 52 Entry Inhibitor 52 Cetrorelix 52 Spinal Disc 52 RNAi Therapeutic 52 Gene Mutation Linked 52 LUX Lung 52 Carcinoid Syndrome 52 PRESEPT study 52 Novel Therapies 52 Initiated Phase 52 Pediatric Diabetes 52 External Beam 52 CLIRS 52 Test Detects 52 evaluating picoplatin 52 oral ghrelin agonist 52 Relapsed Multiple Myeloma 52 Ozarelix 52 placebo controlled Phase 52 Cloretazine ® 52 Clinical Study Shows 52 Alemtuzumab 52 CATIE AD 52 Male Contraceptive 52 II Clinical Trial 52 Anne Penman Laser 52 PLK1 SNALP 52 Pre RELAX AHF 52 Low Incidence 52 omacetaxine mepesuccinate 52 treatment naive genotype 52 Exherin TM 52 Phase IIa trial 52 Achieves Primary Endpoint 52 Diabetic Foot Ulcer 52 HPV cervical dysplasia 52 Opioid Dependence 52 multicenter phase 52 PopSugar Retail 52 Trial Evaluating 52 Fabry Disease 52 unresectable Stage III 52 Desvenlafaxine Succinate 52 REVIVE TA 52 Phase 2b clinical 52 Restless Legs 52 includes TOLAMBA TM 52 CIMZIA TM certolizumab pegol 52 Phase IIa Clinical Trial 52 humanized therapeutic 52 Multiple Ascending Dose 52 Gabapentin GR 52 LymphoStat B TM 52 IMPACT DCM 52 Lung Cancer Survival 52 evaluating tivozanib 52 MARVEL Trial 52 approved incretin mimetic 52 Submits NDA 52 TBC# 52 Randomized Double blind 52 CLIRS trial 52 Cinacalcet 52 Levacor 52 randomized discontinuation 52 undergoing elective percutaneous 52 Phase 2a preventative 52 REMINDER ORLive Presents 52 Evamist TM 52 Phase IIb III 52 Completes Patient Enrolment 52 Cimzia TM 52 JAK2 Inhibitor 52 Phase 1b clinical 52 Critical Limb Ischemia 52 next generation URAT1 52 dextromethorphan quinidine 52 ProCord 52 PEG SN# 52 urocortin 2 52 Evoltra ® 52 Randomized Controlled 52 comparing alemtuzumab 52 NO# [002] 52 ularitide 52 EHR Adoption 52 CCR5 mAb 52 TASKi2 52 FDA Okays 52 OAB overactive bladder 52 targeted radiotherapeutic 52 Platelet Rich Plasma 51 angiotensin analog 51 YOUR LOCAL ANIMAL SHELTER 51 AirBoss Announces 51 Phase III LibiGel 51 Immunosuppressant 51 Technique Helps 51 compound INCB# 51 Metabolic Disorder 51 Autoimmune Disease 51 Glatiramer Acetate 51 Thorough QT 51 intravesical infusion therapy 51 Ataluren 51 sapacitabine CYC# 51 Heterozygous Familial Hypercholesterolemia 51 Pressure Monitoring 51 AIR CF2 51 Shows Promising 51 CYT# potent vascular disrupting 51 Single Incision 51 integrin inhibitors 51 Metabolic Disease 51 KNS # 51 Saforis 51 Reduces Pain 51 StemEx R 51 Inflammatory Disease 51 Post Operative 51 INCB# [001] 51 Pivotal Phase II 51 Laryngeal Cancer 51 EOquin TM phase 51 abdominal laparoscopic surgery 51 TAXUS ATLAS 51 retinal vein occlusion induced 51 hypertension osteoarthritis 51 evaluating ASA# 51 evaluating nimotuzumab 51 Naive Patients 51 Cand5 51 Syncria R 51 Showed Significant 51 Multicenter Randomized 51 multicenter clinical 51 pharmacokinetic PK study 51 Prednisone Against Refractory 51 visilizumab 51 class mGluR5 inhibitor 51 ragweed allergy immunotherapeutic 51 Therapeutic Vaccine 51 Adult Stem Cell Therapy 51 placebo controlled Phase III 51 GSK# [002] 51 evaluating bafetinib 51 Hepatocellular Carcinoma HCC 51 Hemispheric Integration 51 Genes Identified 51 SUPPRELIN R LA 51 assessing T DM1 51 Multicenter Phase 51 EMPOWER Study 51 Resubmission 51 confirmatory clinical 51 Shows Statistically Significant 51 Transcatheter Valve 51 Disorder FSAD 51 Sustained Reduction 51 delivers fluocinolone acetonide FA 51 Reduce Cardiovascular 51 CAMMS# 51 Helps Diagnose 51 ospemifene 51 Pimavanserin 51 Phase 2b RESTORE CLI 51 PREVU x 51 Allovectin 7 51 TM Drug Eluting 51 developed preclinically 51 cathepsin K inhibitor 51 treatment naïve genotype 51 Phase 1b Clinical Trial 51 Phase III clinical 51 investigational protease inhibitor 51 ZOLINZA 51 AeroLEF TM 51 Screenings Offered 51 ACAPODENE 51 Randomized Double Blind 51 Licenses Novel 51 Endologix Powerlink System 51 Aeolus Pharmaceuticals Announces 51 biologic antibody 51 Romidepsin 51 Nanophase Announces 51 Artificial Pancreas 51 Therapeutic Intervention 51 LymphoStat B belimumab 51 PriCara ® 51 CDAD Clostridium difficile 51 riociguat 51 Phase 2b trial 51 Adjuvant Breast Cancer 51 novel oral anticoagulant 51 Vacuum Assisted Closure 51 Phase 2a clinical trials 51 lipid altering 51 Hematological Cancers 51 RSD# oral 51 phase III SIMPADICO 51 TACI Ig 51 R#/MEM 51 opioid bowel dysfunction 51 Metastatic Melanoma 51 Proves Successful 51 randomized multicenter Phase III 51 kidney urologic 51 Rigel R# 51 Clinical Trial Evaluating 51 Causes Symptoms 51 BLA submission 51 Clot Busting 51 R vitespen 51 Project Boveri Find 51 Enrolls First 51 eritoran 51 Ocular Disease 51 candidates Augment ™ 51 occlusion PAO 51 Referenced EEG 51 Enzyme Replacement Therapy 51 AIR CF1 51 alvespimycin 51 albiglutide currently 51 anti VEGF aptamer 51 CCX# B 51 PROACT Phase 2 51 Epratuzumab 51 follicular Non Hodgkin 51 placebo controlled dose escalation 51 Novolimus 51 purinergic receptors P#X# 51 Eculizumab 51 Phase 2b study 51 PDX pralatrexate 51 Phase IIa clinical trials 51 Randomized Phase 51 Epilepsy Drug 51 CB2 selective receptor agonist 51 ofatumumab HuMax CD# 51 leading oral taxane 51 Tanespimycin 51 Minimally Invasive Surgical 51 SinuNase TM 51 Efficacy Results 51 Phase Ib study 51 Anti Angiogenesis 51 Natural Hormone Replacement 51 Cartilage Repair 51 post herpetic neuralgia PHN 51 Combination Treatment 51 Clinical Remission 51 Talotrexin 51 SNT MC# 51 Braintree Rehabilitation 51 Scottish Motion Tabled 51 Clolar ® 51 Therapy Shows Promise 51 Custirsen 51 Elagolix 51 Surfaxin LS 51 Safinamide 51 Hypoactive Sexual Desire Disorder 51 GOUT 51 Tesamorelin 51 fostamatinib 51 Receives Orphan Drug Designation 51 StemEx 51 Phase Ib IIa clinical 51 Glioblastoma Multiforme 51 Receives Approvable Letter 51 Phase IIb clinical 51 Archexin 51 Schizophrenia Drug 51 Shown Effective 51 opioid naive 51 OncoGel 51 Phase 2a 51 Iloperidone 51 benign prostatic hyperplasia enlarged 51 Silodosin 50 TOLAMBA 50 IIa Clinical Trial 50 HCV RESPOND 2 50 pulmonology portfolio 50 Carotid Revascularization Endarterectomy vs. 50 ThermoDox R 50 Rheumatoid Arthritis RA 50 Multicenter Randomized Double 50 Limb Ischemia 50 Catheter Ablation 50 Intensive Outpatient 50 Hematide ™ 50 Asthma COPD 50 Recurrent Prostate Cancer 50 Eases Pain 50 TRANSDUR ™ 50 double blinded placebo 50 Relapsing Multiple Sclerosis 50 Stem Cell Treatment 50 oral Janus kinase 50 Spinal Fractures 50 TM pralatrexate injection 50 Scaffold Based 50 Deforolimus 50 product platforms AZX# 50 Endovascular Valve Edge 50 pivotal Phase III 50 oral calcitonin licensed 50 http:/www.ilgenetics.com 50 Vicor Technologies Announces 50 Study Shows Benefits 50 Talabostat 50 Medicure Announces 50 Percutaneous Tibial Nerve Stimulation 50 Subgroup Analysis 50 AIR CF3 50 Edge STudy 50 Memryte 50 Calmare Pain Therapy 50 Alzheimer disease cognitive impairment 50 Oncotype DX colon cancer 50 subcutaneous methylnaltrexone 50 placebo controlled clinical 50 Stereotactic Body Radiation Therapy 50 Treating Depression 50 Panzem R NCD 50 EXPLORE Xa 50 relapsed MM 50 NAVISTAR R 50 steroid refractory GvHD 50 Biopharmaceuticals AG 50 Healthbeat Report 50 TM Everolimus Eluting 50 Epeius Biotechnologies Corporation 50 Alnylam Biotherapeutics 50 AN# topical anti 50 Antipsychotic Drug 50 Hepatitis C Treatment 50 rasagiline tablets 50 Therapy Helps 50 PROSTVAC ® 50 vagus nerve stimulation VNS 50 GVAX R 50 BioSante Pharmaceuticals Reports 50 Investigational Device Exemption IDE 50 Trofex 50 Phase Ib 50 MEK Inhibitor 50 Childhood Trauma 50 generation PNP inhibitor 50 Sipuleucel T 50 Atypical Hemolytic Uremic Syndrome 50 Fungal Infections 50 serotonin norepinephrine reuptake inhibitor 50 Substance Dependence 50 RECORD1 50 Prostate Cancer Diagnosis 50 Inhaled Liposomal Ciprofloxacin 50 Novel Oral 50 Clinical Decision Making 50 Nuvion 50 Juvenile Idiopathic Arthritis 50 ficlatuzumab 50 GALNS 50 Tumor Response 50 Combivir Kivexa 50 oral prodrug 50 liver resection surgeries 50 NPC 1C 50 Tarvacin Anti Cancer 50 Robot Assisted 50 Hospital Acquired Pneumonia 50 tasisulam 50 CEQ# 50 PrevOnco ™ 50 TRANSDUR ® 50 relapsing multiple sclerosis 50 solanezumab 50 Enzastaurin 50 undergoing Percutaneous Coronary 50 Corlux 50 Curaxin CBLC# 50 Hyphanox 50 Crit Rev 50 Glufosfamide 50 Anticancer Drug 50 LibiGel ® Phase III 50 Lipid Lowering 50 HER2 Positive 50 receptor tyrosine kinase inhibitor 50 cladribine Cladribine Tablets 50 Demonstrates Efficacy 50 intravitreal insert 50 Patient Charting 50 Augment Injectable 50 GW# [003] 50 See CLINICAL PHARMACOLOGY 50 relapsed refractory multiple myeloma 50 refractory metastatic 50 ThGRF 50 Allovectin 7 R 50 Kinase Inhibitors 50 Personalized Immunotherapy 50 Amigal TM 50 interferon alpha IFN 50 Pemphigus 50 Male Infertility 50 Dyloject TM 50 lorvotuzumab mertansine 50 bone marrow reticulin deposition 50 Analytical Tool 50 PEARL SC 50 IIa clinical trials 50 dialectical behavioral 50 protein kinase inhibitors 50 Treatment IND 50 Cognitive Problems 50 hereditary emphysema 50 Phase IIb 50 SMT C# 50 Overactive Bladder OAB 50 intradialytic hypotension IDH 50 evaluating Xcytrin 50 regenerative stem cell 50 dual endothelin receptor antagonist 50 recurrent malignant glioma 50 Avastin adjuvant 50 registrational Phase 50 Rheumatoid Arthritis Drug 50 PEGINTRON TM 50 Valdoxan 50 herpetic keratitis 50 Alexza Pharma 50 Dose escalation 50 Chronic Myeloid Leukemia 50 agonistic human 50 PEGylated interferon beta 1a 50 #I TM# 50 QNEXA ® 50 BiTE antibody MT# 50 Star Caroline Manzo 50 EDEMA4 50 intravenous methylnaltrexone 50 Microplasmin 50 ARISE Phase III 50 recurrent glioblastoma multiforme 50 tosedostat 50 biliary tract cancer 50 Trastuzumab DM1 50 VITAL Trial 50 Newly Diagnosed Multiple Myeloma 50 Metabolic Endocrinology 50 Postdoctoral Position 50 Phase III Trials 50 ATRA IV 50 ELACYT 50 Interferon Alpha 50 Relapsing Remitting Multiple Sclerosis 50 Sleep Diagnostic 50 ZYBRESTAT fosbretabulin 50 CONQUER OB 50 Quinamed 50 Bone Metastases 50 Luramist TM 50 APEX AMI 50 Breast Cancer Treatment 50 ® bortezomib 50 docetaxel Taxotere R 50 Muscle Wasting 50 candidate XP# 50 dose escalation Phase 50 fosbretabulin 50 Pruvel TM 50 Annamycin 50 IgG1 monoclonal antibody 50 APPRAISE 50 Imaging Techniques 50 Phase 2a Clinical Trial 50 Appears Safe 50 Smallpox Vaccination 50 Early Relapsing Multiple 50 dose escalation clinical 50 cilengitide 50 ACTEMRA TM